These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 30512190)
21. Somatostatin receptor 2A in gliomas: Association with oligodendrogliomas and favourable outcome. Kiviniemi A; Gardberg M; Kivinen K; Posti JP; Vuorinen V; Sipilä J; Rahi M; Sankinen M; Minn H Oncotarget; 2017 Jul; 8(30):49123-49132. PubMed ID: 28467778 [TBL] [Abstract][Full Text] [Related]
23. Epigenetic silencing of XAF1 in high-grade gliomas is associated with IDH1 status and improved clinical outcome. Reich TR; Switzeny OJ; Renovanz M; Sommer C; Kaina B; Christmann M; Tomicic MT Oncotarget; 2017 Feb; 8(9):15071-15084. PubMed ID: 28122345 [TBL] [Abstract][Full Text] [Related]
24. Two Unique Glioma Subtypes Revealed. Poh A Cancer Discov; 2016 Apr; 6(4):334-5. PubMed ID: 26917670 [TBL] [Abstract][Full Text] [Related]
25. SHOX2 is a Potent Independent Biomarker to Predict Survival of WHO Grade II-III Diffuse Gliomas. Zhang YA; Zhou Y; Luo X; Song K; Ma X; Sathe A; Girard L; Xiao G; Gazdar AF EBioMedicine; 2016 Nov; 13():80-89. PubMed ID: 27840009 [TBL] [Abstract][Full Text] [Related]
26. Updating the grading criteria for adult diffuse gliomas: beyond the WHO2016CNS classification. Komori T Brain Tumor Pathol; 2020 Jan; 37(1):1-4. PubMed ID: 32060660 [No Abstract] [Full Text] [Related]
27. Brain T1ρ mapping for grading and IDH1 gene mutation detection of gliomas: a preliminary study. Cao M; Ding W; Han X; Suo S; Sun Y; Wang Y; Qu J; Zhang X; Zhou Y J Neurooncol; 2019 Jan; 141(1):245-252. PubMed ID: 30414094 [TBL] [Abstract][Full Text] [Related]
28. Anatomical location differences between mutated and wild-type isocitrate dehydrogenase 1 in low-grade gliomas. Yu J; Shi Z; Ji C; Lian Y; Wang Y; Chen L; Mao Y Int J Neurosci; 2017 Oct; 127(10):873-880. PubMed ID: 27929688 [TBL] [Abstract][Full Text] [Related]
29. Glioma-derived mutations in IDH: from mechanism to potential therapy. Fu Y; Huang R; Du J; Yang R; An N; Liang A Biochem Biophys Res Commun; 2010 Jun; 397(2):127-30. PubMed ID: 20510884 [TBL] [Abstract][Full Text] [Related]
30. Combined IDH1 mutation and MGMT methylation status on long-term survival of patients with cerebral low-grade glioma. Tanaka K; Sasayama T; Mizukawa K; Takata K; Sulaiman NS; Nishihara M; Kohta M; Sasaki R; Hirose T; Itoh T; Kohmura E Clin Neurol Neurosurg; 2015 Nov; 138():37-44. PubMed ID: 26276726 [TBL] [Abstract][Full Text] [Related]
31. Molecular and clinical heterogeneity of adult diffuse low-grade IDH wild-type gliomas: assessment of TERT promoter mutation and chromosome 7 and 10 copy number status allows superior prognostic stratification. Wijnenga MMJ; Dubbink HJ; French PJ; Synhaeve NE; Dinjens WNM; Atmodimedjo PN; Kros JM; Dirven CMF; Vincent AJPE; van den Bent MJ Acta Neuropathol; 2017 Dec; 134(6):957-959. PubMed ID: 29052002 [No Abstract] [Full Text] [Related]
32. Is a prospective trial necessary to suggest a clinical relevance? Pallud J; Duffau H Neuro Oncol; 2014 Sep; 16(9):1295-6. PubMed ID: 25096190 [No Abstract] [Full Text] [Related]
33. Gene Expression Profiling Stratifies IDH1-Mutant Glioma with Distinct Prognoses. Cheng W; Ren X; Zhang C; Cai J; Han S; Wu A Mol Neurobiol; 2017 Oct; 54(8):5996-6005. PubMed ID: 27696222 [TBL] [Abstract][Full Text] [Related]
34. Influence of molecular classification in anaplastic glioma for determining outcome and future approach to management. Back M; Jayamanne DT; Brazier D; Newey A; Bailey D; Schembri GP; Hsiao E; Khasraw M; Wong M; Kastelan M; Guo L; Clarke S; Wheeler H J Med Imaging Radiat Oncol; 2019 Apr; 63(2):272-280. PubMed ID: 30677248 [TBL] [Abstract][Full Text] [Related]
35. High miR-196a and low miR-367 cooperatively correlate with unfavorable prognosis of high-grade glioma. Guan Y; Chen L; Bao Y; Qiu B; Pang C; Cui R; Wang Y Int J Clin Exp Pathol; 2015; 8(6):6576-88. PubMed ID: 26261539 [TBL] [Abstract][Full Text] [Related]
36. In vivo Metabolic Profiles as Determined by Wenger KJ; Hattingen E; Franz K; Steinbach J; Bähr O; Pilatus U Clin Neuroradiol; 2019 Mar; 29(1):27-36. PubMed ID: 28983683 [TBL] [Abstract][Full Text] [Related]
37. Anatomical localization of isocitrate dehydrogenase 1 mutation: a voxel-based radiographic study of 146 low-grade gliomas. Wang Y; Zhang T; Li S; Fan X; Ma J; Wang L; Jiang T Eur J Neurol; 2015 Feb; 22(2):348-54. PubMed ID: 25318355 [TBL] [Abstract][Full Text] [Related]
38. Noninvasively evaluating the grading and IDH1 mutation status of diffuse gliomas by three-dimensional pseudo-continuous arterial spin labeling and diffusion-weighted imaging. Liu T; Cheng G; Kang X; Xi Y; Zhu Y; Wang K; Sun C; Ye J; Li P; Yin H Neuroradiology; 2018 Jul; 60(7):693-702. PubMed ID: 29777252 [TBL] [Abstract][Full Text] [Related]
39. Subgroup characteristics of insular low-grade glioma based on clinical and molecular analysis of 42 cases. Tang C; Zhang ZY; Chen LC; Sun Z; Zhang Y; Qin Z; Yao Y; Zhou LF J Neurooncol; 2016 Feb; 126(3):499-507. PubMed ID: 26586262 [TBL] [Abstract][Full Text] [Related]
40. Isocitrate Dehydrogenase Mutations are Better Prognostic Marker than O6-methylguanine-DNA Methyltransferase Promoter Methylation in Glioblastomas - a Retrospective, Single-centre Molecular Genetics Study of Gliomas. Houdova Megova M; Drábek J; Dwight Z; Trojanec R; Koudeláková V; Vrbková J; Kalita O; Mlcochova S; Rabcanova M; Hajdúch M Klin Onkol; 2017; 30(5):361-371. PubMed ID: 29031038 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]